Canada - English - Health Canada

great earth companies, inc. - d-pantothenic acid (calcium d-pantothenate); biotin; folic acid; calcium (oyster shells, calcium hvp chelate, calcium lactate, calcium gluconate, calcium carbonate, calcium citrate); magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate); manganese (manganese hvp chelate, manganese gluconate); iron (iron hvp chelate, ferrous gluconate); zinc (zinc hvp chelate, zinc gluconate); potassium (potassium gluconate, potassium chloride); selenium (selenium hvp chelate); chromium (chromium hvp chelate); copper (copper gluconate); iodine (kelp); choline (choline bitartrate); inositol; dl-methionine; beta-carotene (provitamin a); vitamin d3 (cholecalciferol); vitamin e (d-alpha tocopheryl acid succinate); ascorbic acid (ascorbic acid); vitamin b1 (thiamine mononitrate); vitamin b2 (riboflavin); vitamin b6 (pyridoxine hydrochloride); vitamin b12 (cyanocobalamin); nicotinamide - tablet - 9.37mg; 9.37mcg; 0.05mg; 125mg; 62.5mg; 1.25mg; 3.75mg; 3.75mg; 12.37mg; 12.5mcg; 3.125mcg; 0.25mg; 0.025mg; 9.37mg; 9.37mg; 9.37mg; 2500unit; 100unit; 50unit; 125mg; 9.37mg; 9.37mg; 9.37mg; 9.37mcg; 9.37mg - d-pantothenic acid (calcium d-pantothenate) 9.37mg; biotin 9.37mcg; folic acid 0.05mg; calcium (oyster shells, calcium hvp chelate, calcium lactate, calcium gluconate, calcium carbonate, calcium citrate) 125mg; magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate) 62.5mg; manganese (manganese hvp chelate, manganese gluconate) 1.25mg; iron (iron hvp chelate, ferrous gluconate) 3.75mg; zinc (zinc hvp chelate, zinc gluconate) 3.75mg; potassium (potassium gluconate, potassium chloride) 12.37mg; selenium (selenium hvp chelate) 12.5mcg; chromium (chromium hvp chelate) 3.125mcg; copper (copper gluconate) 0.25mg; iodine (kelp) 0.025mg; choline (choline bitartrate) 9.37mg; inositol 9.37mg; dl-methionine 9.37mg; beta-carotene (provitamin a) 2500unit; vitamin d3 (cholecalciferol) 100unit; vitamin e (d-alpha tocopheryl acid succinate) 50unit; ascorbic acid (ascorbic acid) 125mg; vitamin b1 (thiamine mononitrate) 9.37mg; vitamin b2 (riboflavin) 9.37mg; vitamin b6 (pyridoxine hydrochloride) 9.37mg; vitamin b12 (cyanocobalamin) 9.37mcg; nicotinamide 9.37mg - vitamins & minerals

Canada - English - Health Canada

great earth companies, inc. - vitamin e (d-alpha tocopherol); selenium (selenium hvp chelate); beta-carotene (provitamin a); dl-methionine; calcium (oyster shells, calcium hvp chelate, calcium gluconate, calcium carbonate, calcium citrate); magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate, magnesium citrate, magnesium fumarate, magnesium malate); zinc (zinc hvp chelate, zinc gluconate, zinc citrate, zinc succinate, zinc fumarate, zinc malate); iron (ferrous gluconate, iron hvp chelate, ferric citrate, ferrous succinate, ferrous fumarate, iron malate); potassium (potassium gluconate, potassium chloride, potassium citrate); manganese (manganese gluconate, manganese hvp chelate); copper (copper gluconate, copper citrate, copper succinate, copper fumarate, copper malate); iodine (potassium iodide, kelp); selenium (selenium hvp chelate); chromium (chromium hvp chelate); vitamin b1 (thiamine hydrochloride); vitamin b2 (riboflavin); vitamin b6 (pyridoxine hydrochloride); vitamin b12 (cyanocobalamin); nicotinamide; folic acid; d-pantothenic acid (calcium d-pantothenate); biotin; choline (choline bitartrate); inositol; ascorbic acid (ascorbic acid, calcium ascorbate); vitamin d3 (cholecalciferol) - tablet (extended-release) - 600unit; 100mcg; 14265unit; 4mg; 600mg; 300mg; 15mg; 18mg; 50mg; 10mg; 1mg; 0.075mg; 25mcg; 25mcg; 100mg; 100mg; 160mg; 160mcg; 160mg; 0.8mg; 160mg; 160mcg; 160mg; 160mg; 1500mg; 200unit - vitamin e (d-alpha tocopherol) 600unit; selenium (selenium hvp chelate) 100mcg; beta-carotene (provitamin a) 14265unit; dl-methionine 4mg; calcium (oyster shells, calcium hvp chelate, calcium gluconate, calcium carbonate, calcium citrate) 600mg; magnesium (magnesium oxide, magnesium hvp chelate, magnesium gluconate, magnesium ascorbate, magnesium citrate, magnesium fumarate, magnesium malate) 300mg; zinc (zinc hvp chelate, zinc gluconate, zinc citrate, zinc succinate, zinc fumarate, zinc malate) 15mg; iron (ferrous gluconate, iron hvp chelate, ferric citrate, ferrous succinate, ferrous fumarate, iron malate) 18mg; potassium (potassium gluconate, potassium chloride, potassium citrate) 50mg; manganese (manganese gluconate, manganese hvp chelate) 10mg; copper (copper gluconate, copper citrate, copper succinate, copper fumarate, copper malate) 1mg; iodine (potassium iodide, kelp) 0.075mg; selenium (selenium hvp chelate) 25mcg; chromium (chromium hvp chelate) 25mcg; vitamin b1 (thiamine hydrochloride) 100mg; vitamin b2 (riboflavin) 100mg; vitamin b6 (pyridoxine hydrochloride) 160mg; vitamin b12 (cyanocobalamin) 160mcg; nicotinamide 160mg; folic acid 0.8mg; d-pantothenic acid (calcium d-pantothenate) 160mg; biotin 160mcg; choline (choline bitartrate) 160mg; inositol 160mg; ascorbic acid (ascorbic acid, calcium ascorbate) 1500mg; vitamin d3 (cholecalciferol) 200unit - vitamins & minerals

United States - English - NLM (National Library of Medicine)

american regent, inc. - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - calcium chloride 100 mg in 1 ml - calcium chloride is indicated in the immediate treatment of hypocalcemic tetany.  other therapy, such as parathyroid hormone or vitamin d, may be indicated according to the etiology of the tetany. it is also important to institute oral calcium therapy as soon as practicable. calcium salts have been used as adjunctive therapy in a number of conditions, including the following: - insect bites or stings, such as black widow spider bites. sensitivity reactions, particularly when characterized by urticaria. as an aid in the treatment of depression due to overdosage of magnesium sulfate. as an aid in the management of the acute symptoms in lead colic. in cardiac resuscitation, particularly after open heart surgery, calcium chloride has been used when epinephrine has failed to improve weak or ineffective myocardial contractions. insect bites or stings, such as black widow spider bites. sensitivity reactions, particularly when characterized by urticaria. as an aid in the treatment of depression due to overdo

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Canada - English - Health Canada

weider health products - pyridoxine hydrochloride; thiamine mononitrate; vitamin b2; folic acid; biotin; vitamin b12; calcium (oyster shells); inositol; choline bitartrate; calcium (oyster shells); calcium (calcium phosphate (dibasic)); magnesium (magnesium oxide); zinc (zinc gluconate); iron (ferrous fumarate); manganese (manganese gluconate); copper (copper gluconate); chromium (chromium trioxide); d-pantothenic acid (calcium d-pantothenate); vitamin a (vitamin a acetate); vitamin e (dl-alpha tocopheryl acetate); vitamin d3; ascorbic acid (calcium ascorbate); calcium (calcium ascorbate); nicotinamide; selenium (selenium oxide); molybdenum (sodium molybdate); iodine (potassium iodide) - tablet - 30mg; 30mg; 30mg; .4mg; 300mcg; 50mcg; 200mg; 100mg; 5mg; 500mg; 50mg; 50mg; 30mg; 18mg; 5mg; 2mg; 11mcg; 30mg; 10000unit; 300unit; 200unit; 500mg; 25mg; 50mg; 10mcg; 12mcg; 650mcg - pyridoxine hydrochloride 30mg; thiamine mononitrate 30mg; vitamin b2 30mg; folic acid .4mg; biotin 300mcg; vitamin b12 50mcg; calcium (oyster shells) 200mg; inositol 100mg; choline bitartrate 5mg; calcium (oyster shells) 500mg; calcium (calcium phosphate (dibasic)) 50mg; magnesium (magnesium oxide) 50mg; zinc (zinc gluconate) 30mg; iron (ferrous fumarate) 18mg; manganese (manganese gluconate) 5mg; copper (copper gluconate) 2mg; chromium (chromium trioxide) 11mcg; d-pantothenic acid (calcium d-pantothenate) 30mg; vitamin a (vitamin a acetate) 10000unit; vitamin e (dl-alpha tocopheryl acetate) 300unit; vitamin d3 200unit; ascorbic acid (calcium ascorbate) 500mg; calcium (calcium ascorbate) 25mg; nicotinamide 50mg; selenium (selenium oxide) 10mcg; molybdenum (sodium molybdate) 12mcg; iodine (potassium iodide) 650mcg - vitamins & minerals

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c: calcium acetate capsules contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), magnesium (unii: i38zp9992a) (magnesium - unii:i38zp9992a), boron (unii: n9e3x5056q) (boron - unii:n9e3x5056q), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - calcium carbonate 1342 mg - indications and usage: calcium-folic acid plus d chewable wafers are indicated, in addition to diet, to help satisfy the distinctive nutritional requirements of individuals under the supervision of a physician for the treatment of calcium deficiency, skeletal weakness and osteoporosis. calcium-folic acid plus d chewable wafers supplementation may be beneficial to individuals who have an insufficient dietary intake of the nutrients contained therein. calcium and vitamin d supplementation may be useful in both preventing and treating osteoporosis. vitamin d supplementation may be beneficial to those who are institutionalized and/or have reduced exposure to sunlight. folic acid, vitamin b 6 , and vitamin b 12 , may help reduce the risk of cardiovascular disease by lowering blood levels of homocysteine. if dietary intake of calcium is inadequate, patients currently taking bisphosphonates for treatment of osteoporosis should be instructed to take calcium and vitamin d daily (calcium-folic

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and d